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Introduction
The solid pseudopapillary neoplasm (SPN) of the pancreas 
is a rare epithelial neoplasm of unknown origin. It accounts 
for 2%–3% of pancreatic tumors in adults but differs from 
other pancreatic neoplasms by a clear preponderance in 
females and a low rate of malignancy.1 Contrary to other 
pancreatic neoplasms, SPN mainly occurs in the younger 
age groups and occasionally in children, and it seems to 
have a predilection for Asian and African American women. 
SPN seldom metastasizes and even in disseminated cases, 
surgical treatment is still an option with an often favorable 
outcome. An increasing incidence has been recorded during 
the last 15 years, which most likely is due to an extended 
use of computed tomography (CT) scans and magnetic 
resonance imaging (MRI), since many tumors are indolent 
and found incidentally.2
The first report of SPN is credited by Lichtenstein,3 who 
resected a tumor of the pancreatic tail which from the 
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2 Rare Tumors
description could have been a pseudopapillary tumor. 
However, the pathology was first thoroughly described by 
Frantz4 in 1959, and the electron microscopic features by 
Hamoudi et al.5 in 1970. The tumor has been referred to by 
several synonyms including the names of the above-men-
tioned pathologists, but in 1996 World Health Organization 
(WHO) renamed it solid pseudopapillary tumor and classi-
fied it as a borderline malignant neoplasm.6
Several publications on SPN are older reviews of earlier 
reported cases some with overlapping series. These studies 
include a considerable number of patients in whom diagno-
sis was made from morphology alone without the latest his-
tologic and immunohistochemical techniques to reveal 
characteristic features. This is important as SPNs share 
radiological and pathologic resemblance with other less 
common pancreatic neoplasms such as neuroendocrine 
tumors, pancreatoblastomas, and acinic cell tumors. 
Therefore, large scale studies, although impressive in num-
ber of patients, may include an unknown amount of cases 
with other tumors than SPN as many of them are dated 
more than 50 and even 70 years back. In this study, we 
describe the clinics, pathology, and outcome of 15 cases of 
SPN that represent different clinical, radiologic, and patho-
logic aspects of this neoplasm.
Patients and methods
The study was performed at a tertiary reference hospital for 
hepato-biliary-pancreatic (HPB) surgery with a catchment 
area of 2.8 million inhabitants. Data were collected from a 
prospectively maintained surgical database of pancreatic 
operations from January 2001 to September 2018.
Patients were examined according to standardized pro-
cedures. All patients had a preoperative triple-phase CT 
scan and if needed supplementary MRI and nuclear medi-
cine imaging. All images were evaluated at our multidisci-
plinary HPB tumor conference in the presence of surgeons, 
oncologists, dedicated radiologists, and nuclear physicians, 
and resectability was assessed. Preoperative biopsies were 
not taken by routine, but all biopsies from other institutions 
were reevaluated by our pathologists.
All operations were performed as open surgery and 
included pancreaticoduodenectomy (Whipple’s operation) 
for tumors in the head of the gland and a distal or left pan-
createctomy with splenectomy for tumors in the body to the 
left of the mesenteric vessels or in the tail of the gland. 
Frozen section of the pancreatic resection margins was 
obtained in all patients to ensure tumor free margins. The 
surgical specimen was sent to the pathology department for 
final diagnosis.
Immunohistochemical studies were performed in all 
specimens using antibodies listed in Table 1. Formalin-
fixed, paraffin-embedded samples were selected for immu-
nohistochemical studies using respective antibodies 
according to manufacturers’ instructions. The staining 
took place on the Omnis from Agilent™ (Agilent 
Technologies, Glostrup, Denmark) utilizing the EnVision 
Flex+ detection kit (GV800) or on the Ventana BenchMark 
Ultra from Roche™ (Roche Diagnostics, Hvidovre, 
Denmark) utilizing the UltraView/OptiView detection kit 
(760-500/760-700). The sections were counterstained with 
haematoxylin.
Data were reviewed by a radiologist (T.S.K.) and a 
pathologist (B.H.F.) with results documented below. Data 
collection was approved by the Danish Data Protection 
Agency (RH-2015-07, nr. 03616) and patients’ consent.
Results
Within the period of our study, 1575 patients underwent 
surgery for tumors of the pancreas of whom 15 patients had 
an SPN (Table 2). Of the 15 patients, 10 were diagnosed 
during the past 5 years. Patients’ median age was 40 (range 
10–87) years, 12 patients were females (80%), and 3 
patients were children or adolescent aged 10, 12, and 
15 years. Ten patients including all minors had abdominal 
symptoms with pain or discomfort; one patient also had 
hematemesis due to tumor growth into the duodenum. SPN 
was discovered incidentally in five patients during exami-
nation for other diseases.
Median tumor size was 5 cm (range 2–16 cm). Abdominal 
symptoms were not related to tumor size. Six tumors were 
in the head, six in the body, and three the tail of the gland.
Preoperative CT scan or biopsy was diagnostic in 11 
patients. CT scan showed characteristic radiologic signs 
of an SPN in eight patients (Figure 1). MRI (four patients), 
18F-fluorodeoxyglucose positron emission tomography 
(18F-FDG-PET) (two patients), and 111In-octreotide scin-
tigraphy (one patient) did not contribute further to the 
diagnosis.
Two patients (numbers 4 and 12, Table 2) had radiologi-
cal signs of a neuroendocrine tumor with enhancement of 
contrast uptake in the arterial phase. The first of the two 
patients had a tumor with invasion into the duodenum and 
encasement of the superior mesenteric vein, an 8 cm × 5 cm 
large liver metastasis with involvement of the second and 
third hepatic segment and metastases to 3 out of 16 lymph 
Table 1. Immunohistochemical procedures. 
Antibody Antigen (Clone) Manufacturer Platform
Chromogranin LK2H10 Roche™ Ventana
Synaptophysin DAK-SYNAP Agilent™ Omnis
Progesterone 1E2 Roche Ventana
Vimentin V9 Roche Ventana
CD10 SP67 Agilent Omnis
CD56 123C3 Agilent Omnis
Cyclin D1 SP4-R Roche Ventana
β-catenin 4 Roche Ventana
α1-trypsin Poly Dako Ventana
α1-anti-chymotrypsin Poly Dako Ventana
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nodes. An 111In-octreotide scintigraphy showed an increased 
activity of the pancreatic tumor (Grades 3–4) but neither of 
the liver metastasis (Grade 3 uptake, equivalent to physio-
logic liver uptake) nor of the lymph nodes.
A preoperative biopsy was obtained in 10 patients, and 
nine biopsies including three fine-needle aspiration (FNA) 
were diagnostic. In one patient (number 4), the diagnosis 
was suggestive of a pseudopapillary neoplasm alternatively 
a neuroendocrine tumor and in another patient the result 
was inconclusive.
Fourteen patients underwent operation, one patient 
aged 87 years was not operated due to old age. Eight 
patients had a pancreaticoduodenectomy, one with con-
comitant resection of a liver metastasis, and six patients 
had a distal pancreatectomy with splenectomy. Resection 
of the porto-mesenteric vein was performed in two 
patients including the patient with metastatic disease, and 
one patient (number 14) had an additional resection of 
the right colon due to inflammatory adhesions between 
tumor and the bowel. One patient (number 9) had a total 
gastrectomy and a pancreaticoduodenectomy due to a 
gastric cancer. The tumor infiltrated near to the pancreas 
and at the time of operation the assessment was that the 
tumor had spread to the gland. Histopathological exami-
nation showed, however, that the tumor in the pancreas 
was separate from the gastric adenocarcinoma and was in 
fact an SPN.
There was only one tumor (patient number 4) expressing 
gross malignant features with infiltration into the duode-
num, lymph node, and liver metastases. This was the only 
tumor with a high proliferation rate (ki67 23%). The pri-
mary tumor and the metastases revealed same morphology 
and immunohistochemical characteristics. Only one tumor 
showed focal perineural invasion (patient number 15), 
while no tumor showed vascular invasion of tumor cells. 
The resected mesenteric veins and the transverse colon 
only showed inflammatory reaction.
Table 2. Clinical data of 15 patients with solid pseudopapillary tumor of the pancreas.
Patient Age Tumor 
site
Tumor 
size (cm)
Metastases Radiographic 
appearance
Calcification Preoperative 
diagnosis made
Operation Survival 
(months)
 From CT/
MRI
From 
biopsy
 
1 30 Head 6 Cystic/solid No Yes PD 204.9
2a 23 Body 5 Cystic/solid Yes Yes Yes DP 106.1
3 15 Tail 9 Cystic/solid No No DP 110.9
4 68 Head 7 Nodes and 
liver
Cystic/solid No Yes PDb 89.7
5 40 Tail 5 Cystic/solid Yes Yes Yes DP 83.2
6 12 Head 5 Cystic/solid Yes Yes PDb 69.2
7 68 Head 15 Cystic Yes Yes nd PD 43.8
8 41 Head 3 Cystic Yes Yes Yes PD 40.3
9a 73 Body – No nd PD 39.1
10 87 Tail 16 Cystic/solid Yes Yes Yes nd 38.1
11 30 Body 7 Cystic/solid Yes Yes Yes DP 31.6
12 44 Body 4 Solid No nd DP 29.0
13 21 Body 15 Cystic/solid No Yes PD 22.3
14a 10 Head 6 Cystic/solid Yes nd PD 17.5
15 51 Body 2 Cystic/solid No nd DP 13.0
PD: pancreaticoduodenectomy; DP: distal pancreatectomy; nd: not done; CT: computed tomography; MRI: magnetic resonance imaging.
aMale.
bVascular resection.
Figure 1. A 30-year old woman with a solid pseudopapillary 
neoplasm of the pancreas. Axial contrast-enhanced arterial 
phase CT image shows a well-defined heterogenous mass in the 
tail of the pancreas with peripheral calcifications (arrow).
4 Rare Tumors
Tumor pathology was similar in adults and children 
(Table 3). Pseudopapilla formation and vacuolated cyto-
plasm with eosinophilic globules were common findings 
followed by cholesterol clefts and the presence of foamy 
macrophages and clear cells (Figures 2–5). Most tumors 
showed immunohistochemically activity for vimentin, 
CD10, and β-catenin as well as α1-antitrypsin and 
α1-antichymotrypsin. Activity of the neuroendocrine 
marker synaptophysin was also a common finding while 
focal chromogranin activity was seen in two tumors 
(Table 4).
Table 3. Histologic analysis of 15 solid pseudopapillary tumors.
Patient Pseudopapilla Clear 
cells
Calcification Cholesterol 
clefts
Foamy 
macrophages
Vacuolated 
cytoplasm
Eosinophile 
globules
High-grade 
transformation
Vascular 
invasion
Perineural 
invasion
1 Yes Yes Yes Yes Yes Yes Yes No No No
2a Yes Yes No Yes No Yes Yes No No No
3 Yes No No No Yes No No No No No
4 Yes No No No No Yes No Yes No No
5 Yes No No No No Yes Yes No No No
6 Yes No No No Yes Yes Yes No No No
7 Yes Yes Yes Yes No Yes Yes No No No
8 Yes Yes Yes No No Yes No No No No
9a Yes No No No Yes Yes Yes No No No
10 Yes No No No No Yes Yes No No No
11 Yes No Yes Yes No Yes Yes No No No
12 Yes Yes No Yes Yes Yes Yes No No No
13 Yes Yes No No Yes No Yes No No No
14a No Yes No Yes Yes Yes Yes No No No
15 Yes Yes No Yes Yes Yes Yes No No Yes
aMale.
Figure 2. Solid pseudopapillary neoplasm of the pancreas with 
characteristically histologic morphology. Pseudopapilla with 
hyaline stroma, HE × 100.
Figure 3. Tumor cells with vacuolated cytoplasm, HE × 175.
Figure 4. Eosinophile globules marked by arrow, HE × 200.
Figure 5. Cholesterol and foamy macrophages, HE × 80.
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In one patient (number 4), an electron microscopy was 
needed to differentiate between a neuroendocrine tumor 
and SPN, and in the remaining patients, the final diagnosis 
was made by histopathologic examination.
There were no postoperative medical complications. 
Two patients had surgical complications. One patient had a 
pancreatic leakage after a distal pancreatectomy, and the fis-
tula was treated conservatively by drainage. The other 
patient had a bowel fistula from his ileotransversostomy 
after a concomitant colonic resection. The fistula was 
resected with re-anastomosis. One patient had a late compli-
cation with a stricture of the hepaticojejunostomy 6 years 
after her operation, and a neo-hepaticojejunostomy was per-
formed after abortive attempts to dilate the anastomosis 
with transhepatic (P.T.C.) balloon catheter. All 15 patients 
are still alive 13.0–196.8 months (median 40.3 months) after 
diagnosis, and the 14 operated cases without recurrence.
Discussion
The SPN of the pancreas is a special entity as it has no 
resemblance to other pancreatic tumors. There have been 
speculations that the tumor cells have another origin than 
from the pancreas.7 Since SPN is mainly seen in females, it 
has been hypothesized that it develops from displaced cells 
from the ovarian genital ridge, which is close to the primor-
dial pancreas, or from pluripotent embryonic cells in the 
pancreas under influence of female hormones.
Several papers and casuistic communications on SPN 
have been published since the first description in 1933 
including two large-scale reviews of English-written papers 
one covering the period from 1933 to 2003 (718 patients)8 
and the other from 1961 to 2012 (2744 patients).2 This 
review also includes reference to 553 patients published in 
Chinese papers between 1996 and 2009.9 The number of 
patients with SPN recorded at our hospital during a study 
period of almost 18 years conforms to the number in a 
Swedish review of 16 cases from a catchment area of the 
same size as ours found between 1991 and 2010 and thus 
reflects the seldom occurrence of SPN in Scandinavia.10 In 
one paper from Egypt11 and another from Israel,12 the num-
ber of SPN was higher with relation to total number of 
operated pancreatic tumors, 24/765 vs 32/1320 patients, 
respectively, than in the two Scandinavian studies.
As expected, we found a clear female preponderance 
among the patients, but the median age of 40 years was 
higher than the average age of 22.0, 27.2, and 28.5 years 
reported in the three large reviews above.
Most patients present with pain or non-specific abdomi-
nal symptoms, but tumor may also be indolent and, there-
fore, attain a considerable size before it is diagnosed. 
Jaundice or obstruction of the main pancreatic duct are 
uncommon, and clinical biochemistry is uncharacteristic 
and there are no useful tumor markers in plasma.8
Over the last decade, the number of reported SPN has 
increased concurrently with the more frequent use of CT 
scan and MRI. Ten of our patients were diagnosed during the 
last 5 years, but only five patients were found incidentally 
while the remaining patients had abdominal symptoms.
We found an almost equal distribution of tumors in the 
head or the body and tail, while location in the body and tail 
is reported to occur in about 60% of cases.2,8 Median tumor 
diameter at diagnosis was 5 cm which is in accordance with 
the reported size of 6.0–8.6 cm. The gross anatomy typi-
cally reveals an encapsulated tumor with cystic degenera-
tion and hemorrhage. Smaller tumors tend to be more solid 
while larger tumors are friable as they develop cystic 
degeneration and bleeding with growth.
Table 4. Immunohistochemic analysis of 15 solid pseudopapillary tumors.
Patient Chromogranin Synaptophysin Progesteron Vimentin CD10 CD56 Cyclin 
D1
β-
catenin
α1-
antitrypsin
α1-
antichymotrypsin
1 No Yes Yes Yes Yes Yes No Yes Yes Yes
2a Yes Weak – Yes – Yes – – Yes Yes
3 Weak Weak Yes – Yes Yes – – – –
4 Yes Yes No Yes No – – No Yes Yes
5 Weak Yes Yes Yes Yes Yes Yes Yes Yes Yes
6 Weak Yes Yes Yes – – – – No –
7 No Yes Yes Yes Yes Yes Yes Yes Yes Yes
8 No Weak Yes Yes Yes Yes Yes Yes Yes Yes
9a No Yes No No Yes Yes Yes Yes No No
10 No Yes Yes Yes Yes Yes – Yes – –
11 No Yes Yes Yes Yes Yes Yes Yes Yes Yes
12 No Yes Yes Yes Yes Yes Yes Yes – –
13 No Yes Yes Yes Yes Yes Yes Yes Yes Yes
14a No No Yes Yes Yes Yes Yes Yes – Yes
15 No Yes – Yes Yes – – Yes – Yes
aMale—not done.
6 Rare Tumors
Ultrasonography, CT scan, and MRI generally show the 
same features with an encapsulated tumor consisting of solid 
and cystic components, occasionally with rim-like calcifica-
tions in the capsule as well as intraparenchymatous calcifica-
tions.13,14 The lesion has well defined margins often without 
dilatation of the pancreatic duct. Ultrasonography demon-
strates various echogenic and hypoechogenic components, 
CT scan components of various density, and MRI lesions 
with a high-signal intensity on T1 and low signal intensity on 
T2 series representing hemorrhagic areas.14 Angiographically, 
the tumor is usually found to be avascular or hypovascular. 
None of the radiological features, however, are characteristic 
of SPN, and the finding can also be seen in other pancreatic 
tumors especially cystic neuroendocrine tumors and pancre-
atoblastoma. The 18F-FDG-PET varies in activity since 
tumor cells may have a high as well as a low metabolism.15
SPN is a cellular neoplasm with cells arranged in several 
layers around fibrovascular stalks, giving rise to the pseu-
dopapillary structure. The histologic presence of a pseudo-
papillary architecture, hyaline globules, cholesterol clefts, 
foamy macrophages, and nuclear grooving with the absence 
of neuroendocrine (salt-and-pepper) chromatin are charac-
teristic of a SPN.16,17 The ultrastructure consists of non-
desmosome-like junctions and electron-dense granules that 
may contain α-1 antitrypsin.16
Immunohistochemically, SPN shows an abnormal stain-
ing pattern with both nuclear and cytoplasmic positivity for 
β-catenin and loss of E-cadherin from the cytoplasmic mem-
brane.18,19 Other common positive markers include proges-
terone receptor, α-1 antitrypsin receptor, and CD10.20
SPNs often express immunoreactivity for the neuroen-
docrine markers synaptophysin and neuron-specific eno-
lase and less common chromogranin. If the histologic and 
immunohistochemical appearance are not sufficiently char-
acteristic to be diagnostic, electron microscopy may be 
helpful.
Common differential diagnoses are pancreatoblastoma, 
acinic cell tumor, and neuroendocrine tumor, which radio-
graphically as well as immunohistochemically bear several 
similarities.21,22 Nuclear and cytoplasmic β-catenin expres-
sion is reported in pancreatoblastoma, but the histologic 
appearance with cells formatting so-called squamoid cor-
puscles and dense bands of fibrous stroma are characteristic 
and different from SPN.23 Pancreatoblastoma is most com-
mon in children and, contrary to SPN, has a male prepon-
derance. Acinic cell tumors are rare in children but have a 
histologic appearance that resembles pancreatoblastoma 
but without squamoid corpuscles. Neuroendocrine tumors 
(islet-cell tumors) may be functioning with hormone secre-
tion or non-functioning. Neuroendocrine tumor markers 
like synaptophysin, chromogranin, and CD56 may be vari-
ously expressed in SPN.
The differentiation between non-functioning neuroen-
docrine tumors and SPNs may be difficult. Two of our 
patients (numbers 4 and 12, Table 1) had a tumor with a 
radiological appearance of a neuroendocrine tumor. Tumor 
from the second patient had synaptophysin activity but also 
showed activity for vimentin, CD10, α1-antitrypsin, α1-
antichymotrypsin, and especially β-catenin, which was 
decisive for the SPN diagnosis.
The diagnosis of patient number 4 was more difficult. A pre-
operative biopsy from the primary tumor and the liver metasta-
sis suggested a pseudopapillary tumor. 111In-octreotide 
scintigraphy showed activity of the pancreatic tumor but nei-
ther of the liver metastasis nor of the metastatic lymph nodes. 
Although 111In-octreotide activity has a high specificity for 
neuroendocrine tumors, activity may be found in other neo-
plasms as well as in non-neoplastic conditions.24 Postoperative 
pathologic analysis of the primary tumor and metastasis 
showed activity of synaptophysin and chromogranin A without 
reaction for CD10 and β-catenin. The Ki67 was 23% of the 
pancreatic tumor and 2% of the liver metastasis, thus the dif-
ferential diagnosis could be a neuroendocrine carcinoma. 
However, the tumor had a positive staining for vimentin, α1-
antitrypsin, and α1-antichymotrypsin which are characteristic 
of an SPN. Electron microscopy could demonstrate dense bod-
ies, but neither neurosecretory vesicles nor cytoplasmatic annu-
lated lamellae or junctions, and the final diagnosis was an SPN.
The differentiation between SPN with malignant and 
benign potential is difficult as signs of malignant behavior 
except from metastases are controversial.25 According to the 
WHO classification, clear criteria of malignancy are vascu-
lar and nerve sheath invasion or lymph node and liver 
metastases in which cases tumor is designated as solid-pseu-
dopapillary carcinoma.6 Tumor size larger than 5 cm and 
growth into the capsule and out into peripancreatic tissue 
have all been related to malignancy.2,26 Only one of our 
patients had metastatic disease with liver and lymph node 
metastases and a tumor infiltrating the duodenum. Seven 
patients had a tumor size larger than 5 cm but none have had 
recurrence so far. One tumor had perineural growth while 
the two cases with involvement of the mesenteric vessels 
and adhesion to the colon in another patient were due to 
inflammatory reaction and not tumor infiltration.
The only curative treatment is radical surgery with free 
resection margins,11,12,27 and adjuvant oncologic therapy 
has no impact on survival. Due to the localized growth of 
STN, this is possible in most cases. Local tumor infiltration 
or metastatic disease is not a contraindication for operation 
since radical resection including all metastatic tissue may 
result in long-term survival and cure. The overall 5-year 
survival rate is more than 95.0% in large-scale reviews and 
the recurrence rate up to 6.6%.2,8,9
One pediatric study falls outside these results.28 Among 
41 patients with a median age of 13 years, seven (17.1%) 
had relapse from 33 to 94 months after operation, two had 
local recurrence, and five intraperitoneal dissemination. 
The authors found that the only risk factors of relapse were 
a positive resection margin and an age under 13.5 years. 
The first factor is not surprising while the last may reflect 
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the outcome of less aggressive surgery in minors. There is 
no evidence that children should have a higher recurrence 
rate than adults.
Primary metastatic disease as well as recurrence have 
been treated according to different oncologic protocols 
including 5-FU, S-1, gemcitabine, sunitinib, and transarte-
rial embolization of liver metastases (TACE).29,30 However, 
the results are casuistic, and the general opinion is that 
oncologic treatment has a limited effect on SPN which calls 
for aggressive surgical resection including metastases and 
in case of recurrence.
In conclusion, pancreatic SPN is a rare neoplasm with a 
malignant potential but a favorable prognosis. Radical sur-
gery is associated with cure or long-term survival even in 
case of metastases. Recurrence after radical surgery is sel-
dom and should be treated surgically, since oncologic treat-
ment has limited effect. Thorough histologic analysis with 
immunohistochemistry is important to differentiate SPN 
from pancreatoblastoma, acinic, and neuroendocrine tumors.
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